HN2009003002A - Compuestos de piridopirimidinonas inhibidores de pi3k-alfa - Google Patents

Compuestos de piridopirimidinonas inhibidores de pi3k-alfa

Info

Publication number
HN2009003002A
HN2009003002A HN2009003002A HN2009003002A HN2009003002A HN 2009003002 A HN2009003002 A HN 2009003002A HN 2009003002 A HN2009003002 A HN 2009003002A HN 2009003002 A HN2009003002 A HN 2009003002A HN 2009003002 A HN2009003002 A HN 2009003002A
Authority
HN
Honduras
Prior art keywords
pyridopirimidinones
pi3k
alfa
inhibiting
compounds
Prior art date
Application number
HN2009003002A
Other languages
English (en)
Spanish (es)
Inventor
David Lamb Peter Matthews
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of HN2009003002A publication Critical patent/HN2009003002A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HN2009003002A 2007-04-10 2009-10-09 Compuestos de piridopirimidinonas inhibidores de pi3k-alfa HN2009003002A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92289907P 2007-04-10 2007-04-10

Publications (1)

Publication Number Publication Date
HN2009003002A true HN2009003002A (es) 2014-03-24

Family

ID=39627802

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2009003002A HN2009003002A (es) 2007-04-10 2009-10-09 Compuestos de piridopirimidinonas inhibidores de pi3k-alfa

Country Status (31)

Country Link
US (1) US8513266B2 (cg-RX-API-DMAC7.html)
EP (1) EP2139484B9 (cg-RX-API-DMAC7.html)
JP (3) JP2010523670A (cg-RX-API-DMAC7.html)
KR (1) KR101626435B1 (cg-RX-API-DMAC7.html)
CN (2) CN102727498B (cg-RX-API-DMAC7.html)
AU (1) AU2008236562B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0810206A2 (cg-RX-API-DMAC7.html)
CA (1) CA2683641C (cg-RX-API-DMAC7.html)
CO (1) CO6251254A2 (cg-RX-API-DMAC7.html)
CR (1) CR11100A (cg-RX-API-DMAC7.html)
DK (1) DK2139484T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2009000243A (cg-RX-API-DMAC7.html)
EA (1) EA020022B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP099724A (cg-RX-API-DMAC7.html)
ES (1) ES2430614T3 (cg-RX-API-DMAC7.html)
HN (1) HN2009003002A (cg-RX-API-DMAC7.html)
HR (1) HRP20130688T1 (cg-RX-API-DMAC7.html)
IL (1) IL201284A (cg-RX-API-DMAC7.html)
MA (1) MA31358B1 (cg-RX-API-DMAC7.html)
ME (1) ME00936B (cg-RX-API-DMAC7.html)
MX (1) MX2009010930A (cg-RX-API-DMAC7.html)
MY (1) MY150697A (cg-RX-API-DMAC7.html)
NZ (1) NZ580110A (cg-RX-API-DMAC7.html)
PL (1) PL2139484T3 (cg-RX-API-DMAC7.html)
PT (1) PT2139484E (cg-RX-API-DMAC7.html)
RS (1) RS52939B (cg-RX-API-DMAC7.html)
SI (1) SI2139484T1 (cg-RX-API-DMAC7.html)
TN (1) TN2009000400A1 (cg-RX-API-DMAC7.html)
UA (1) UA100979C2 (cg-RX-API-DMAC7.html)
WO (1) WO2008124161A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200906764B (cg-RX-API-DMAC7.html)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200726767A (en) * 2005-07-04 2007-07-16 Astrazeneca Ab Chemical compounds 2
BRPI0617159B8 (pt) * 2005-10-07 2021-05-25 Exelixis Inc compostos de piridopirimidinone inibidores de pi3ka, composições que os contem e processo para preparo
AU2006302179C1 (en) * 2005-10-07 2013-06-20 Exelixis, Inc. N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
CN101528231A (zh) 2006-08-16 2009-09-09 埃克塞利希斯股份有限公司 在癌症的治疗中使用pi3k和mek调控剂
US8188113B2 (en) * 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
SA08280783B1 (ar) * 2007-01-11 2011-04-24 استرازينيكا ايه بي مشتقات بيريدوبيريميدين كمثبطات pde4
ME00936B (me) 2007-04-10 2012-06-20 Exelixis Inc Postupci liječenja kancera upotrebom piridopirimidinonskih inhibitora pi3k alfa
KR101586774B1 (ko) * 2007-04-11 2016-01-19 엑셀리시스, 인코포레이티드 암의 치료에 사용하기 위한 ｐｉ３ｋ­알파의 퀴녹살린 억제제를 포함하는 병용 요법
WO2010022128A1 (en) * 2008-08-20 2010-02-25 Schering Corporation Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
AR072940A1 (es) 2008-08-20 2010-09-29 Schering Corp Derivados de piridina y pirimidina sustituidos con etinilo y su uso en el tratamiento de infecciones virales
JP5731976B2 (ja) 2008-08-20 2015-06-10 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 置換ピリジン誘導体および置換ピリミジン誘導体ならびにそれらのウイルス感染の治療における使用
WO2010022126A1 (en) 2008-08-20 2010-02-25 Schering Corporation Azo-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
WO2011100319A1 (en) 2010-02-09 2011-08-18 Exelixis, Inc. Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k and mtor in combination with autophagy inhibitors
US20130156768A1 (en) * 2010-08-26 2013-06-20 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with braf inhibitors for the synergistic treatment of proliferative diseases
JP5792819B2 (ja) 2010-09-14 2015-10-14 エクセリクシス， インク． Ｐｉ３ｋ−デルタの阻害剤ならびにそれらの使用法および製造法
WO2012065019A2 (en) 2010-11-12 2012-05-18 Exelixis, Inc. Pyridopyrimidinone inhibitors of p13k alpha
WO2012158960A2 (en) * 2011-05-17 2012-11-22 H. Lee Moffitt Cancer Center & Research Institute, Inc. Melanocortin 1 receptor ligands and methods of use
TW201306842A (zh) * 2011-06-15 2013-02-16 Exelixis Inc 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
BR112014002121A2 (pt) * 2011-07-28 2017-02-21 Genentech Inc modelo de câncer de mama de animal knock-in não humano pik3ca h1047r
WO2013056067A1 (en) * 2011-10-13 2013-04-18 Exelixis, Inc. Compounds for use in the treatment of basal cell carcinoma
JP6013498B2 (ja) 2011-11-01 2016-10-25 エクセリクシス， インク． リンパ増殖性悪性疾患の治療のためのホスファチジルイノシトール３−キナーゼ阻害剤としてのｎ−（３−｛［（３−｛［２−クロロ−５−（メトキシ）フェニル］アミノ｝キノキサリン−２−イル）アミノ］スルホニル｝フェニル）−２−メチルアラニンアミド
WO2013071264A1 (en) * 2011-11-11 2013-05-16 Intellikine, Llc Combination of kinase inhibitors and uses thereof
CA2860051A1 (en) 2011-12-27 2013-07-04 Kadmon Corporation, Llc Methods for treatment of breast cancer nonresponsive to trastuzumab
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
BR112014032346A2 (pt) 2012-06-26 2017-06-27 Del Mar Pharmaceuticals métodos para tratamento de malignidades resistentes ao inibidor de tirosina-quinase em pacientes com polimorfismos genéticos ou desregulações de ahi1 mutações empregando dianidrogalactitol, diacetildianidrogalactitol, dibromodulcitol, ou análogos ou derivados destes
US8980259B2 (en) * 2012-07-20 2015-03-17 Novartis Ag Combination therapy
PL2882440T3 (pl) 2012-08-07 2019-07-31 Novartis Ag Kombinacje farmaceutyczne zawierające inhibitor b-raf, inhibitor egfr i opcjonalnie inhibitor pi3k-alfa
JP2016519684A (ja) 2013-04-08 2016-07-07 デニス エム ブラウン 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物
US9950194B2 (en) 2014-09-09 2018-04-24 Mevion Medical Systems, Inc. Patient positioning system
EP3424505A4 (en) 2016-03-04 2019-10-16 Taiho Pharmaceutical Co., Ltd. PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
CR20190062A (es) * 2016-08-15 2019-05-22 Pfizer Inhibidores de cdk2/4/6
JP7027699B2 (ja) * 2017-05-09 2022-03-02 住友ゴム工業株式会社 タイヤトレッドおよびタイヤ
BR112020015581A2 (pt) 2018-01-31 2021-02-02 Deciphera Pharmaceuticals, Llc terapia de combinação para o tratamento de tumores estromais gastrointestinais
SG11202007287XA (en) 2018-01-31 2020-08-28 Deciphera Pharmaceuticals Llc Combination therapy for the treatment of mastocytosis
TWI790364B (zh) 2018-03-19 2023-01-21 日商大鵬藥品工業股份有限公司 包含烷基硫酸鈉之醫藥組合物
KR20220045189A (ko) 2019-08-12 2022-04-12 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양을 치료하는 방법
WO2021030405A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
JP7677646B2 (ja) * 2019-12-10 2025-05-15 ザ・トラスティーズ・オブ・インディアナ・ユニバーシティー 複製タンパク質ａ（ｒｐａ）－ｄｎａ相互作用阻害剤
CN119950433A (zh) 2019-12-30 2025-05-09 德西费拉制药有限责任公司 非晶型激酶抑制剂制剂及其使用方法
PL4084779T3 (pl) 2019-12-30 2025-02-24 Deciphera Pharmaceuticals, Llc Kompozycje 1-(4-bromo-5-(1-etylo-7-(metyloamino)-2-okso-1,2-dihydro-1,6-naftyrydyn-3-ylo)-2-fluorofenylo)-3-fenylomocznika
KR102195221B1 (ko) 2019-12-31 2020-12-24 서울대학교산학협력단 포스파티딜이노시톨 3-키나아제 억제제 및 프로그램화 세포 사멸 단백질 1 억제제를 포함하는, 삼중음성 유방암의 방사선 병용 치료용 약학적 조성물
CN111358952B (zh) * 2020-04-15 2022-03-15 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种抗肿瘤药物组合物及其制剂和应用
CN118678960A (zh) * 2021-11-18 2024-09-20 安可诺瓦治疗公司 用于治疗癌症的方法和组合物
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7019002B2 (en) * 2001-12-11 2006-03-28 Pharmacia & Upjohn, S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
EP2277867B1 (en) * 2002-07-15 2012-12-05 Symphony Evolution, Inc. Compounds, pharmaceutical compositions thereof and their use in treating cancer
CA2555724A1 (en) * 2004-02-18 2005-09-09 Warner-Lambert Company Llc 2-(pyridin-3-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
US20080255162A1 (en) * 2004-05-04 2008-10-16 Warner-Lambert Company Llc Pyrrolyl Substituted Pyrido[2,3-D]Pyrimidin-7-Ones and Derivatives Thereof as Therapeutic Agents
WO2007004698A1 (ja) * 2005-07-06 2007-01-11 Sbc Corporation 漏洩電流検出装置及び漏洩電流検出方法
BRPI0617159B8 (pt) * 2005-10-07 2021-05-25 Exelixis Inc compostos de piridopirimidinone inibidores de pi3ka, composições que os contem e processo para preparo
EA201200669A1 (ru) 2005-10-07 2012-11-30 Экселиксис, Инк. ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
AU2006302179C1 (en) * 2005-10-07 2013-06-20 Exelixis, Inc. N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
CN101528231A (zh) 2006-08-16 2009-09-09 埃克塞利希斯股份有限公司 在癌症的治疗中使用pi3k和mek调控剂
KR101099926B1 (ko) * 2006-09-15 2011-12-28 화이자 프로덕츠 인코포레이티드 피리도 (2,3-ｄ) 피리미디논 화합물 및 이의 ｐｉ3 억제제로서의 용도
ME00936B (me) 2007-04-10 2012-06-20 Exelixis Inc Postupci liječenja kancera upotrebom piridopirimidinonskih inhibitora pi3k alfa
EP2142543B8 (en) 2007-04-11 2013-07-03 Exelixis, Inc. Pyrido [2, 3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
KR101586774B1 (ko) * 2007-04-11 2016-01-19 엑셀리시스, 인코포레이티드 암의 치료에 사용하기 위한 ｐｉ３ｋ­알파의 퀴녹살린 억제제를 포함하는 병용 요법
EP2142544B8 (en) 2007-04-11 2013-07-03 Exelixis, Inc. Pyrido [2, 3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
JP2012504628A (ja) * 2008-09-30 2012-02-23 エグゼリクシス， インコーポレイテッド ＰＩ３ＫαおよびｍＴＯＲのピリドピリミジノン阻害剤

Also Published As

Publication number Publication date
CA2683641C (en) 2016-08-16
EP2139484A1 (en) 2010-01-06
CO6251254A2 (es) 2011-02-21
BRPI0810206A2 (pt) 2014-10-21
TN2009000400A1 (en) 2010-12-31
CR11100A (es) 2010-01-19
EA020022B1 (ru) 2014-08-29
DOP2009000243A (es) 2010-10-31
ECSP099724A (es) 2010-03-31
DK2139484T3 (da) 2013-10-21
JP2014034576A (ja) 2014-02-24
AU2008236562B2 (en) 2013-11-07
HRP20130688T1 (en) 2013-09-30
JP2010523670A (ja) 2010-07-15
IL201284A0 (en) 2010-05-31
PL2139484T3 (pl) 2013-12-31
EP2139484B9 (en) 2014-06-11
UA100979C2 (ru) 2013-02-25
CN101715345A (zh) 2010-05-26
MX2009010930A (es) 2010-01-20
WO2008124161A1 (en) 2008-10-16
EP2139484B1 (en) 2013-07-17
RS52939B (sr) 2014-02-28
US20100209420A1 (en) 2010-08-19
EP2139484B8 (en) 2013-08-21
KR20100016354A (ko) 2010-02-12
CA2683641A1 (en) 2008-10-16
MA31358B1 (fr) 2010-05-03
PT2139484E (pt) 2013-10-31
EA200970932A1 (ru) 2010-04-30
CN102727498B (zh) 2016-08-03
CN102727498A (zh) 2012-10-17
KR101626435B1 (ko) 2016-06-01
US8513266B2 (en) 2013-08-20
IL201284A (en) 2016-06-30
ZA200906764B (en) 2010-08-25
SI2139484T1 (sl) 2013-10-30
HK1139863A1 (en) 2010-09-30
ES2430614T3 (es) 2013-11-21
NZ580110A (en) 2012-06-29
MY150697A (en) 2014-02-28
JP2014139217A (ja) 2014-07-31
ME00936B (me) 2012-06-20
AU2008236562A1 (en) 2008-10-16

Similar Documents

Publication Publication Date Title
HN2009003002A (es) Compuestos de piridopirimidinonas inhibidores de pi3k-alfa
CR11099A (es) Uso de compuestos inhibidores de quinaxolina de p13k-alfa para el tratamiento del cancer
GT200500158A (es) Derivados de amino-5,5-difenilimidazolona para la inhibicion de la b-secretasa
DOP2009000159A (es) Inhibidores de la poli(adp-ribosa) polimerasa
TR201900306T4 (tr) Mek inhibitörlerini kullanma yöntemleri.
CY1118232T1 (el) Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων
GT201100181A (es) "inhibidores de proteina cinasa"
UY32730A (es) Inhibidores de cyp17
ECSP067080A (es) DIFENILIMIDAZOPIRIMIDINA Y AMINAS IMIDAZOL COMO INHIBIDORES DE ß-SECRETASA
TW200738725A (en) Unsaturated mTOR inhibitors
MX2009003157A (es) Pirazoliltienopiridinas terapeuticas.
MX2009000657A (es) Composiciones y metodos para el tratamiento de mucositis.
TN2011000291A1 (en) Purine compounds
TN2009000451A1 (en) Intrvenous and oral dosing of a direct-acting and reversible p2y12 inhibitor
MY145795A (en) Pyrazoline compounds
CO6382123A2 (es) Antagonistas de la via hedgehog de ftalazina disustituida
EA201170344A1 (ru) Азаиндольные ингибиторы iap
MX2015012386A (es) Inhibidores de la cinasa cdk9.
GT200500191A (es) Derivados de pirido - pirimidina, su preparacion, su aplicacion en terapeutica
DK2231590T3 (da) Antitumorforbindelser
MX2010001303A (es) Compuestos terapeuticos.
CY1117805T1 (el) Αντιμετωπιση οστεοπορωσης
HN2009003001A (es) Uso de compuestos inhibidodres de quinaxolina de pi3k-alfa para el tratamiento del cancer
DOP2009000241A (es) Inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cancer
GT200600268A (es) 4-anilino-3-quinolincarbonitrilos para el tratamiento del cáncer